The development and clinical success of G12C mutant-specific KRAS inhibitors was a landmark achievement in anti-cancer drug development, as the oncogenic KRAS protein had long been considered an intractable therapeutic target [5, 6, 9]. The gene discussed is KRAS; the disease is cancer.